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ABSTRACT
There is currently no licensed vaccine for noroviruses, and development is hindered, in part, by an incomplete understanding of
the host adaptive immune response to these highly heterogeneous viruses and rapid GII.4 norovirus molecular evolution. Emer-
gence of a new predominant GII.4 norovirus strain occurs every 2 to 4 years. To address the problem of GII.4 antigenic variation,
we tested the hypothesis that chimeric virus-like particle (VLP)-based vaccine platforms, which incorporate antigenic determi-
nants from multiple strains into a single genetic background, will elicit a broader immune response against contemporary and
emergent strains. Here, we compare the immune response generated by chimeric VLPs to that of parental strains and a multiva-
lent VLP cocktail. Results demonstrate that chimeric VLPs induce a more broadly cross-blocking immune response than single
parental VLPs and a similar response to a multivalent GII.4 VLP cocktail. Furthermore, we show that incorporating epitope site
A alone from one strain into the background of another is sufficient to induce a blockade response against the strain donating
epitope site A. This suggests a mechanism by which population-wide surveillance of mutations in a single epitope could be used
to evaluate antigenic changes in order to identify potential emergent strains and quickly reformulate vaccines against future epi-
demic strains as they emerge in human populations.
IMPORTANCE
Noroviruses are gastrointestinal pathogens that infect an estimated 21 million people per year in the United States alone. GII.4
noroviruses account for >70% of all outbreaks, making them the most clinically important genotype. GII.4 noroviruses undergo
a pattern of epochal evolution, resulting in the emergence of new strains with altered antigenicity over time, complicating vac-
cine design. This work is relevant to norovirus vaccine design as it demonstrates the potential for development of a chimeric
VLP-based vaccine platform that may broaden the protective response against multiple GII.4 strains and proposes a potential
reformulation strategy to control newly emergent strains in the human population.
As the primary cause of acute gastroenteritis, noroviruses an-nually infect more than 21 million people in the United States
(1) and result in an estimated 200,000 deaths in children under 5
years of age worldwide (2). Furthermore, norovirus-associated
economic losses due to health care costs and lost productivity total
an estimated 5.5 billion dollars per year in the United States alone
(3). Because of these staggering health and economic burdens, a
norovirus vaccine is highly desirable for those who work in high-
risk environments, including health care settings, schools and
daycare centers, nursing homes, military barracks, and restau-
rants. Unfortunately, progress toward an effective vaccine has
been slow due in part to the lack of a tissue culture system, the
highly heterogeneous nature of different genogroups and geno-
types, and lack of understanding of the mechanisms and duration
of protective immunity in humans.
Noroviruses are positive-sense RNA viruses and members of
the Caliciviridae family. They are divided into five genogroups;
genogroups I and II (GI and GII, respectively) infect humans and
are further divided into at least 9 and 22 genotypes, respectively (4,
5). The 7.5-kb norovirus genome is divided into three open
reading frames (ORFs). ORF1 encodes the nonstructural proteins,
ORF2 encodes VP1, the major capsid protein, and ORF3 encodes
VP2, the minor capsid protein (6). VP1 is divided into the shell (S)
and protruding (P) domains, and upon expression of the major
capsid gene, VP1 dimers self-assemble into virus-like particles
(VLPs), which are antigenically and morphologically comparable
to native virions. The capsid P domain is further divided into the
P1 and P2 subdomains. The capsid P2 subdomain is the most
surfaced-exposed area of the virion and interacts with antibodies
and cellular binding ligands, the histo-blood group antigens
(HBGAs) (7–12). HBGAs are a diverse group of carbohydrates
differentially expressed on mucosal surfaces and differentially tar-
geted by the various norovirus genotypes (11–14). Importantly, in
the absence of a cell culture model for human norovirus, the
blockade assay (15), a correlate of human protection (16, 17),
evaluates potential antibody neutralization by measuring the abil-
ity of monoclonal antibodies or serum to block VLP-ligand inter-
actions.
Evolutionary patterns and contributions to disease outbreaks
vary by genogroup and genotype. GI.1 (Norwalk virus) and other
GI noroviruses exhibit a limited capacity for antigenic change over
time (18), while GII.4 noroviruses demonstrate a pattern of
epochal evolution, whereby a circulating strain is replaced by an
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emergent strain, likely in response to herd immunity (15, 19–23).
GII.3 noroviruses exhibit an evolutionary rate similar to that of
GII.4 noroviruses, but the evolutionary mechanism appears to be
different (24). GII.2 noroviruses, on the other hand, exhibit lim-
ited antigenic evolution over time (25). Of the remaining human
norovirus genotypes, little is known about their evolutionary
mechanisms. In terms of disease burden, GII.4 noroviruses con-
sistently account for over 70% of all outbreaks (26). Other GI and
GII genotypes contribute to norovirus disease outbreaks at lower
levels, but relative contributions vary by year and geographic lo-
cation. Since an effective norovirus vaccine should protect against
the strains most commonly responsible for outbreaks, GII.4 no-
roviruses are the most medically relevant group to vaccinate
against; however, considering the heterogeneous nature of noro-
viruses, a vaccine strategy that would protect against a wide array
of viruses would be beneficial. In addition, due to antigenic vari-
ation in GII.4 noroviruses, the GII.4 component of a vaccine
would likely need to be reformulated over time, reflecting the
antigenic characteristics of newly evolved contemporary strains.
There is uncertainty in the field as to the duration of protective
immunity following norovirus infection. While early human chal-
lenge studies suggested that protection lasts between 6 months
and 2 years (27, 28), the acquisition of norovirus illness is dose
dependent (29, 30), and the challenge dose used in these early
studies was likely much higher than that of a typical human expo-
sure, suggesting that results minimized the ability of the immune
response to control a natural infection (31). Other studies show-
ing strain replacement and extinction of early GII.4 epidemic
strains suggested that many individuals may mount more-long-
term protective immunity (13, 32, 33). Recent work using a com-
munity-based transmission model suggests that the duration of
immune protection is much longer, from 4 to 8 years (31), mean-
ing that an efficacious norovirus vaccine may provide some indi-
viduals protection for several years.
Several norovirus vaccine formulations are currently in human
clinical trails. Results testing the GI.1 component of a commercial
norovirus vaccine, the only human challenge norovirus vaccine
efficacy study to date, indicate that 3 weeks after administration of
an intranasal VLP-based GI.1 vaccine, gastroenteritis was reduced
by 47% (16). Interestingly, 31% of the placebo group did not
become ill despite administration of 10 times the 50% infectious
dose (ID50) (16), supporting earlier findings that some individuals
may have had preexisting immunity to the virus (32). Longer-
term monitoring of these participants is being conducted to de-
termine the duration of protection provided by this vaccine.
Several different VLP-based vaccine platforms are currently
being investigated, including GII.4 consensus VLP and multiva-
lent VLP approaches. Immunization studies in mice have demon-
strated that multivalent VLP vaccines induce a blockade response
against VLPs representing strains included in the vaccine formu-
lation and also broaden the blockade response against VLPs rep-
resenting strains not included in the vaccine (34).
Our work involves the development of strategies to simultane-
ously investigate the capacity of rational structure-guided antigen
design to expand and broaden the antigenic properties within a
formulation and rapidly reformulate a preexisting GII.4 norovirus
vaccine. In the manuscript, we designed and constructed a chime-
ric GII.4 vaccine by admixing previously identified blockade
epitopes (15, 19, 22) from multiple strains into a single vaccine
background to induce a more broadly blocking immune response
than a single GII.4 strain vaccine. Here, we utilize an alphavirus
replicon (virus replicon particle [VRP]) system (35), which both
acts as an adjuvant (36, 37) and allows for the expression of the
norovirus capsid gene and the formation of VLPs in immunized
mice (34, 38). As proof of principle, we demonstrate that a chime-
ric GII.4 capsid vaccine can induce a more broadly blocking im-
mune response than a single GII.4 strain capsid, inducing robust
blockade titers of GII.4 VLPs from strains isolated in 1987 through
2012 (representing strains GII.4-1987 through GII.4-2012, re-
spectively), including those strains not included in the chimeric
VLP. Furthermore, this broadened response is similar to a multi-
valent vaccine formulation, which was previously shown to
broaden blockade responses (34). Our work provides a new con-
ceptual template for the design of multivalent VLP vaccine formu-
lations using structure-guided antigen design and represents a
new and promising GII.4 norovirus vaccine strategy.
MATERIALS AND METHODS
Structure-guided antigen design. Capsid sequences for major GII.4 out-
break strains were aligned, and structural homology models based on the
Research Collaboratory for Structural Bioinformatics (RCSB) PBD struc-
ture 2OBT were made for strains representing GII.4-1987 (GenBank
accession number AAK50355.1), GII.4-1997 (JQ478407), GII.4-2002
(JQ478408), GII.4-2006 (JQ478409), GII.4-2009 (ADD10375), and
GII.4-2012 (AFV08795.1). Changing residues in the capsid P2 subdomain
were noted, and putative epitopes were defined and characterized as pre-
viously reported (15, 19, 22). Chimeric capsid sequences were created
between strains whereby the GII.4-2006 A, D, and/or E epitope sites were
replaced with comparable epitope site sequence(s) from one or more het-
erologous GII.4 strains. These sequences were synthesized (BioBasic),
cloned into expression vector pVR21, and verified by sequencing.
Production of VRPs and VLPs. VRPs expressing the norovirus capsid
gene were produced as previously described (35). Briefly, pVR21 3526 is
an expression vector encoding the Venezuelan equine encephalomyelitis
(VEE) genome yet lacks the VEE structural genes. The norovirus ORF2
gene was synthesized (BioBasic) and inserted into pVR21 3526 in place of
the VEE structural genes behind the 26S promoter. RNA was made from
the VEE-norovirus ORF2 construct, as well as from two additional sepa-
rate plasmids expressing either the VEE 3526 E1 and E2 glycoprotein
genes or the capsid gene. RNA from all three constructs was electropo-
rated into BHK cells, and VRPs were harvested 48 h later and purified by
high-speed centrifugation. Titers of VRPs were determined by counting
fluorescent cells detected with fluorescein isothiocyanate (FITC)-labeled
antibody. For production of VLPs, BHK cells were inoculated with VRPs
as previously described (15), and VLP production was confirmed by elec-
tron microscopy, enzyme immunoassay, and carbohydrate binding.
VLP-carbohydrate ligand-binding antibody blockade assays. Pig
gastric mucin type III (PGM) (Sigma Chemicals) contains HBGAs -1,2-
fucose (H antigen) and -1,4-fucose (Lewis antigen) (13, 19, 39) and has
been validated as a substrate for norovirus VLP antibody blockade assays.
Blockade assays were performed as previously described (15). VLPs
bound to PGM were detected by rabbit anti-GII.4 norovirus polyclonal
serum. The percent control binding was defined as the VLP-ligand bind-
ing level in the presence of test antibody or serum compared to the bind-
ing level in the absence of antibody, multiplied by 100. All sera were
tested for blockade potential at 2-fold serial dilutions ranging from 0.0098
to 5%. Data shown are the average of sera from five individual mice and
represent two replicates that are indicative of similar data from two inde-
pendent trials. Sigmoidal dose response analysis was performed as previ-
ously described (15). Fifty percent effective concentrations (EC50s)
among VLPs were compared using one-way analysis of variance
(ANOVA) with Bonferroni’s posttest. A P value of 0.05 was considered
significant.
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Mouse immunizations. Groups of five 5- to 7-week-old BALB/c mice
were immunized by footpad injection with 5  104 VRPs expressing the
GII.4 norovirus capsid gene from strain GII.4-1987, GII.4-2002, GII.4-
2006, GII.4-2009, GII.4-2006.87A, or GII.4-2006.87A.02E or an equal
multivalent mix of strains GII.4-1987, GII.4-2002, and GII.4-2006 and
were boosted on day 21. Mice were euthanized and serum was harvested at
7 days postboost. Animal work performed in this study was approved by
the Animal Care and Use Committee of the University of North Caroli-
na—Chapel Hill.
RESULTS
Design of chimeric VLP vaccine. Previous work has demon-
strated both genetic and antigenic changes over time in major
GII.4 norovirus strains, including changes in at least three block-
ade epitope sites that are linked to antigenic variation and the
emergence of new epidemic strains in human populations (15, 19,
22). We aligned epitope site A, D, and E amino acid sequences
from three GII.4 strains representing an ancestral strain, GII.4-
1987, an early pandemic strain, GII.4-2002, and a more contem-
porary pandemic strain, GII.4-2006b to illustrate the changes over
time in these epitopes (Fig. 1A) and mapped their locations on the
surface of the capsid P2 dimer (Fig. 1B). Previous work indicates
that blockade epitopes are portable among GII.4 strains, confer-
ring blockade antibody reactivity gains and losses to the back-
ground strain (15, 19, 22). We then used structure-guided design
to create synthetic genes in which broad combinations of time-
ordered blockade epitopes were assembled into a single chimeric
construct, which was used to produce a novel VLP-based vaccine
with broadened immunogenicity. We created a single-epitope
chimera, GII.4-2006.87A, which is comprised of the GII.4-2006
background with epitope site A (residues 294, 296 to 298, 368, and
372) from GII.4-1987, and a double-epitope chimera, GII.4-
2006.87A.02E, which is comprised of the GII.4-2006 background
with epitope site A from GII.4-1987 and epitope site E (residues
407, 412, and 413) from GII.4-2002 (Fig. 1C).
Individual GII.4 strain VLPs do not induce broad blockade
responses. To determine the breadth of blockade induced by sin-
gle parental GII.4 strain VLPs, we first immunized groups of five
BALB/c mice with VRPs expressing the major capsid gene of GII.4
strains from 1987, 2002, 2006, or 2009 and then used sera from
these mice to assess the ability of each VLP to induce a blockade
response against a panel of GII.4 strain VLPs representing over 25
years of variation, including GII.4-1987, GII.4-1997, GII.4-2002,
GII.4-2006, GII.4-2009, and GII.4-2012. Sera from mice immu-
nized with GII.4-1987 VRPs were able to block carbohydrate-VLP
interaction for early strains GII.4-1987, GII.4-1997, and GII.4-
2002 but not for late strain GII.4-2006, GII.4-2009, or GII.4-2012
(Fig. 2A). Likewise, sera from mice immunized with GII.4-2002
were able to block only the early strains (GII.4-1987, GII.4-1997,
and GII.4-2002) and not the late strains (GII.4-2006, GII.4-2009,
and GII.4-2012) (Fig. 2B). Conversely, sera from mice immunized
FIG 1 Chimeric VLP vaccine constructs. (A) Sequences from GII.4-1987, GII.4-2002, and GII.4-2006 were aligned, and residues in blockade epitopes A, D, and
E are shown. (B) Capsid P2 dimer (gray) showing the location of blockade epitopes A (pink), D (green), and E (orange). (C) Chimeric VLP P2 dimers. Differential
epitope A residues from parental strain GII.4-1987 (A294V, R297H, N298D, S368T, and E372N) are inserted into the parental GII.4-2006 strain background to
create chimeric VLP GII.4-2006.87A. Chimeric VLP GII.4-2006.87A.02E contains the same GII.4-1987 residue substitutions as well as epitope E substitutions
(N412T and V413G).
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with GII.4-2006 did not block early strain GII.4-1987, GII.4-1997,
or GII.4-2002 but efficiently blocked homotypic GII.4-2006 and
heterotypic late strains GII.4-2009 and GII.4-2012 (Fig. 2C). Sera
from mice immunized with GII.4-2009 did not block early strain
GII.4-1987, GII.4-1997, or GII.4-2002 but blocked GII.4-2006,
GII.4-2009, and GII.4-2012 (Fig. 2D). Overall, our data show that
none of the parental-strain VLPs we tested induces a broad block-
ade response against ancestral and contemporary GII.4 strains,
consistent with previous work demonstrating GII.4 antigenic
variation over time (20, 21, 23).
Chimeric VLPs retain blockade epitopes of the component
VLPs. To determine if chimeric VLPs retain the antigenic proper-
ties of multiple GII.4 strains, we tested the blockade ability of sera
from mice immunized with parental-strain VRPs (GII.4-1987,
GII.4-2002, GII.4-2006, or GII.4-2009) to block VLP-ligand inter-
actions for two chimeric VLPs. Sera from mice immunized against
parental strain GII.4-1987, GII.4-2002, GII.4-2006, or GII.4-2009
were all able to block both GII.4-2006.87A and GII.4-
2006.87A.02E VLP-carbohydrate interactions but to differing de-
grees (Fig. 3). Sera from mice immunized against GII.4-1987 (Fig.
3A) blocked GII.4-2006.87A and GII.4-2006.87A.02E VLPs to
similar degrees, while sera from mice immunized against GII.4-
2002 (Fig. 3B) blocked GII.4-2006.87A.02E VLPs significantly
better (P  0.05) than GII.4-2006.87A VLPs, likely because this
chimeric VLP contained a GII.4-2002 blockade epitope. Sera from
mice immunized against GII.4-2006 (Fig. 3C) and GII.4-2009
(Fig. 3D) blocked GII.4-2006.87A VLPs significantly more effi-
ciently (P  0.05) than GII.4-2006.87A.02E VLPs. These results
demonstrate that chimeric VLPs can maintain antigenic blockade
properties of multiple GII.4 strains.
Chimeric VLPs induce a broadly blocking immune response
against homotypic- and heterotypic-strain VLPs. Since anti-
genic variation in GII.4 noroviruses is a major hurtle to develop-
ment of an efficacious vaccine, creating a vaccine that induces
neutralization against a broad panel of strains is ideal. Since chi-
meric VLPs retain the antigenic properties of multiple GII.4
strains, we tested their potential as a vaccine. In order to determine
whether a chimeric VLP can induce a more broadly blocking im-
mune response than parental VLP strains, we developed VRPs
that express the capsid genes for chimeric sequences GII.4-
2006.87A and GII.4-2006.87A.02E. We immunized groups of five
BALB/c mice with VRPs expressing either the GII.4-2006.87A or
GII.4-2006.87A.02E capsid gene and compared the ability of the
sera from these mice to block VLP-ligand interactions against our
VLP panel with previously mentioned representative GII.4 strains
isolated from 1987 to 2012. Unlike the parental VLPs, which
FIG 2 Single-strain VRPs do not induce a broad blockade response. BALB/c mice were immunized with VRPs expressing the norovirus capsid gene from
parental strain GII.4-1987, GII.4-2002, GII.4-2006, or GII.4-2009 via footpad injection. Sera from mice immunized with GII.4-1987, GII.4-2002, GII.4-2006, and
GII.4-2009 VRPs were evaluated for the ability to block VLP interaction with carbohydrate ligand pig gastric mucin type III (PGM) for VLPs representing strains
GII.4-1987, GII.4-1997, GII.4-2002, GII.4-2006, GII.4-2009, and GII.4-2012. For each VLP, the mean percentage of control binding (percentage of the VLP
bound to PGM in the presence of sera compared to the amount of VLP bound with no sera present) was fit to a sigmoidal curve, and the mean EC50 of serum was
calculated (percentage of serum required to block 50% of the VLP-PGM interaction). Sera that did not block a particular VLP were assigned a value of 10% (2
times the upper limit of detection) for statistical analysis and placed as a data point above the dotted line (upper limit of detection).
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blocked only a subset of the VLPs tested, sera from mice immu-
nized with GII.4-2006.87A or GII.4-2006.87A.02E VRPs were able
to block all of the VLP strains tested from GII.4-1987 through
GII.4-2012 (Fig. 4). GII.4-2006.87A sera exhibited significantly
more robust blockade responses (P  0.05) than GII.4-
2006.87A.02 sera for VLPs representing strains GII.4-1987 (Fig.
4A), GII.4-1997 (Fig. 4B), GII.4-2006 (Fig. 4D), GII.4-2009 (Fig.
4E), and GII.4-2012 (Fig. 4F), where between 1.5 to 3.9 times
more GII.4-2006.87A.02E sera was needed for EC50 blockade.
Blockade responses to GII.4-2002 VLPs were not significantly dif-
ferent between sera from GII.4-2006.87A- and GII.4-2006.
87A.02E-immunized mice (Fig. 4C). Importantly, this demon-
strates that the incorporation of epitope A alone is sufficient to
attain a broadened blockade response against multiple GII strains.
Comparison of immune responses elicited by chimeric VLPs
versus a multivalent formulation of VLPs. Previous work in our
lab showed that immunizing with a multivalent VLP vaccine for-
mulation induced a broadly blocking response against both VLPs
representing strains included and those not included in the for-
mulation (34). We wanted to compare the blockade response in-
duced by immunizing with chimeric VRPs versus immunization
with a multivalent VRP cocktail. Since GII.4-2006.87A VRPs gen-
erally induced a stronger broadened blockade response than
GII.4-2006.87A.02E VRPs, we used GII.4-2006.87A to represent
the chimeric immunization scheme. We immunized groups of
five BALB/c mice with VRPs expressing either a chimeric (GII.4-
2006.87A) capsid gene or a multivalent cocktail of parental VRPs
expressing GII.4-1987, GII.4-2002, and GII.4-2006 capsid genes.
Sera from mice immunized with the multivalent cocktail dis-
played broad blockade activity, in agreement with previous stud-
ies (34), although the blockade potential against different strains
varied between the multivalent sera and the chimeric sera (Fig. 5).
Sera from mice immunized with the multivalent cocktail were able
to block GII.4-1987 VLP-ligand interaction at levels similar to
those of chimeric sera (Fig. 5A). Multivalent serum EC50 blockade
titers were significantly different (P  0.05) for GII.4-1997 VLPs
(2.2 times lower) and GII.4-2002 (6.8 times lower) VLPs from
those of chimeric sera (Fig. 5B and C). Chimeric sera blocked late
strains GII.4-2006, GII.4-2009, and GII.4-2012 significantly more
efficiently (P  0.05) than sera from the multivalent-VLP-vacci-
nated mice (Fig. 5D to F), with 4, 2.9, and 2.1 times more multi-
valent sera required, respectively, for EC50 blockade. When the
blockade responses induced by single-strain, multivalent-strain,
and chimeric-strain immunizations are compared, sera against a
single parental strain blocks the homotypic VLP-ligand interac-
tion significantly better (P  0.05) than either multivalent sera or
chimeric sera for GII.4-1987 (Fig. 6A), GII.4-2002 (Fig. 6B),
GII.4-2006 (Fig. 6C), and GII.4-2009 (Fig. 6D) VLPs. However,
for all VLPs, sera from chimeric GII.4-2006.87A or multivalent
formulations blocked as well as or better than sera from the closest
heterotypic strain. Chimeric GII.4-2006.87A and multivalent sera
blocked GII.4-1987 VLPs significantly more efficiently (P  0.05)
than GII.4-2002 sera (Fig. 6A), and multivalent sera blocked
GII.4-2002 VLPs significantly more efficiently (P  0.05) than
GII.4-1987 sera (Fig. 6B). GII.4-2006.87A sera blocked GII.4-2006
VLPs significantly more efficiently (P  0.05) than GII.4-2009
sera (Fig. 6C), while blockade of GII.4-2009 VLPs was equivalent
for GII.4-2006 and GII.4-2006.87A sera (Fig. 6D). Overall, our
data show that chimeric and multivalent vaccine formulations can
broaden the blockade response against homotypic- and hetero-
typic-strain VLPs compared to the response with a single-strain
vaccine formulation.
DISCUSSION
GII.4 antigenic variation is a major complication in norovirus
vaccine design since this genotype evolves quickly and accounts
for over 70% of all norovirus outbreaks. GII.4 strains emerge every
2 to 4 years by escaping human herd immunity, suggesting that
frequent vaccine reformulation may be necessary in order to con-
tinuously protect against the GII.4 genotype. An approach that
uses an approved backbone gene with targeted replacements of
key antigenic epitopes for eliciting protective immunity offers a
FIG 3 Single-strain VRP serum blockade response against chimeric VLPs.
BALB/c mice were immunized with VRPs expressing the norovirus capsid
gene from parental strain GII.4-1987, GII.4-2002, GII.4-2006, or GII.4-2009
via footpad injection. Sera from mice immunized with GII.4-1987, GII.4-2002,
GII.4-2006, and GII.4-2009 VRPs were evaluated for the ability to block VLP
interaction with carbohydrate ligand PGM for chimeric VLPs GII.4-2006.87A
and GII.4-2006.87A.02E. For each VLP, the mean percentage of control bind-
ing (percentage of the VLP bound to PGM in the presence of sera compared to
the amount of VLP bound with no sera present) was fit to a sigmoidal curve,
and the mean EC50 of serum was calculated (percentage of serum required to
block 50% of the VLP-PGM interaction). Sera that did not block a particular
VLP were assigned a value of 10% (2 times the upper limit of detection) for
statistical analysis and placed as a data point above the dotted line (upper limit
of detection). Statistical significance was determined by one-way ANOVA with
a Bonferroni posttest (*, P  0.05). Blockade of parental VLPs is shown as a
reference for each serum sample.
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strategy for improving vaccine performance while streamlining
FDA approval processes for human use. In the manuscript, we
demonstrate that detailed molecular characterization of key vary-
ing blockade epitopes, coupled with structure-guided antigen de-
sign and synthetic biology, is able to yield a VLP vaccine formula-
tion that induces a more robust and cross-reactively broadly
blocking immune response than a single-outbreak strain capsid.
This and recent work from our group using a similar epitope
transfer strategy in dengue virus (40) demonstrate that structure-
guided antigen design provides a novel method of mapping im-
munogenic targets in medically important RNA viruses. The ap-
proach is also compatible with RSV mimotope vaccines based on
synthetic reconstruction of key neutralizing epitopes on a portable
scaffold nanoparticle (41), in our case, a norovirus VLP-based
vaccine platform.
Our work demonstrates that a single-strain VLP can induce a
stronger blockade response against the parental strain than either
chimeric or multivalent VLPs. Whether this is due to differences
in the number of epitopes from each strain presented, immune
interference, or both is unknown. However, both immune inter-
ference and antigen dose are known to affect the strength of the
immune response. Immune interference has been noted in other
multivalent norovirus vaccines (42), multivalent VLP-based hu-
man papillomavirus (HPV) vaccines (43), live-virus vaccines (44,
45), and killed/recombinant vaccines (46). However, immune re-
sponses elicited by chimeric VLP-based vaccines should not be
subject to immune interference since only one type of particle is
present in the vaccine. This notion, coupled with our data show-
ing that multivalent and chimeric sera more efficiently blocked
strains that were most represented in their respective vaccines,
FIG 4 Comparison of chimeric VRP serum blockade response against parental GII.4 VLPs. BALB/c mice were immunized with VRPs expressing the norovirus
capsid gene from chimeric sequences GII.4-2006.87A and GII.4-2006.87A.02E via footpad injection. Sera from mice immunized with GII.4-2006.87A and
GII.4-2006.87A.02E VRPs were evaluated for the ability to block VLP interaction with carbohydrate ligand PGM for VLPs representing strains GII.4-1987,
GII.4-1997, GII.4-2002, GII.4-2006, GII.4-2009, and GII.4-2012. For each VLP, the mean percentage of control binding (percentage of the VLP bound to PGM
in the presence of sera compared to the amount of VLP bound with no sera present) was fit to a sigmoidal curve, and the mean EC50 of serum was calculated
(percentage of serum required to block 50% of the VLP-PGM interaction). Sera that did not block a particular VLP were assigned a value of 10% (2 times the
upper limit of detection) for statistical analysis and placed as a data point above the dotted line (upper limit of detection). Statistical significance was determined
by one-way ANOVA with a Bonferroni posttest (*, P  0.05).
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suggests that antigen dose and epitope dominance are more likely
to account for differences in immune induction. Despite having a
stronger blockade against a homotypic strain, the immune re-
sponse to a single GII.4 VLP does not broadly block heterologous
strains, suggesting that the ability of a single strain to induce a
neutralizing response against closely related circulating GII.4
strains is limited. This is problematic for a GII.4 vaccine since
emerging strains may quickly escape the herd immunity elicited
by a single strain. Previous work suggests that an increase in dos-
age of a single-strain VLP would probably not increase blockade
breadth, whereas increasing the dosage of a chimeric or multiva-
lent vaccine could potentially compensate for the comparative
weakness in blockade strength (34).
Our results also suggest that incorporating immunodominant
epitope site A from one strain into another is sufficient to induce
a blockade response against the donor strain. These data are con-
sistent with earlier work showing that 25 to 55% of a polyclonal
blockade response targets epitope site A in multiple pandemic
years (15, 20, 22, 23). Of our two chimeric VLPs, GII.4-2006.87A
VLPs induce a generally stronger blockade response against all
VLPs tested from GII.4-1987 through GII.4-2012, with the excep-
tion of GII.4-2002, for which there was no difference between the
two chimeric VLPs. This demonstrates that epitope site A alone
was sufficient to induce a blockade response against early strains
GII.4-1987, GII.4-1997, and GII.4-2002 and supports earlier work
demonstrating that epitope site A is likely immunodominant in
GII.4 (22). The addition of GII.4-2002 epitope site E in GII.4-
2006.87A.02E did not significantly increase the blockade response
against GII.4-2002, suggesting that this is a minor site or that
additional residues are required in this epitope to fully recapitu-
late the antigenic properties of the epitope.
Preexposure history and its effects on the immune response to
FIG 5 Comparison of chimeric versus multivalent VRP serum blockade response against parental GII.4 VLPs. BALB/c mice were immunized with VRPs
expressing either the norovirus capsid gene from chimeric sequence GII.4-2006.87A or a multivalent mix of VRPs expressing the capsid gene from GII.4-1987,
GII.4-2002, and GII.4-2006 via footpad injection. Sera from mice immunized with GII.4-2006.87A and multivalent VRPs were evaluated for the ability to block
VLP interaction with carbohydrate ligand PGM for VLPs representing strains GII.4-1987, GII.4-1997, GII.4-2002, GII.4-2006, GII.4-2009, and GII.4-2012. For
each VLP, the mean percentage of control binding (percentage of the VLP bound to PGM in the presence of serum compared to the amount of VLP bound with
no serum present) was fit to a sigmoidal curve, and the mean EC50 of serum was calculated (percentage of serum required to block 50% of the VLP-PGM
interaction). Sera that did not block a particular VLP were assigned a value of 10% (2 times the upper limit of detection) for statistical analysis and placed as a data
point above the dotted line (upper limit of detection). Statistical significance was determined by one-way ANOVA with a Bonferroni posttest (*, P  0.05).
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subsequent norovirus infections are not well understood. Block-
ade data from outbreak serum samples collected over time suggest
that exposure to new GII.4 strains does not boost cross-blocking
antibodies to previous strains, but this may be due to several fac-
tors besides a lack of conserved neutralization sites, including lim-
itations in methods capable of identifying cross-neutralizing
epitopes, the long duration of time between infections in an indi-
vidual, or a quickly waning antibody response. Whether a success-
ful norovirus vaccine containing vaccine components to multiple
strains would boost previous immune responses, providing a
more broadly cross-reactive response over time, is a topic of future
investigation and will need to be resolved over time.
Public health preparedness requires a platform strategy to sur-
vey disease prevalence in human populations, categorize sequence
variation, identify antigenic variants that may seed future out-
breaks, and inform vaccine design. A similar strategy to the one
used for reformulation of the annual influenza virus vaccine could
be implemented to address reformulation of future norovirus vac-
cines. The current influenza paradigm involves a synchronized
effort by public health agencies and centers around the world to
conduct ongoing epidemiological antigenic testing and genetic
characterization of influenza virus isolates and make predictions
about which may cause the greatest threat to human health world-
wide (47). Norovirus surveillance systems, like the CDC Calicinet
(48) and the European NoroNet, while relatively new, represent
key emerging platforms for developing a similar, widespread, co-
ordinated effort to track norovirus epidemiology and emergent
strain identification for improved vaccine design (49). Epidemio-
logical work on GII.4-2012 Sydney has shown that this strain was
present at low levels in the population for at least a year before its
emergence as a major circulating strain (50), showing that new
strains are likely present early enough before emergence to allow
detection, antigenic testing, and targeted surveillance. As is done
for influenza virus, panels of defined antibodies could be used to
FIG 6 Parental strain blockade comparisons among homotypic, heterotypic, chimeric, and multivalent sera. BALB/c mice were immunized with VRPs
expressing either the norovirus capsid gene from GII.4-1987, GII.4-2002, GII.4-2006, GII.4-2009, chimeric sequences GII.4-2006.87A or GII.4-2006.87A.02E, or
a multivalent mix of VRPs expressing the capsid gene from GII.4-1987, GII.4-2002, and GII.4-2006 via footpad injection. Sera from these mice were evaluated
for the ability to block VLP interaction with carbohydrate ligand PGM for VLPs representing strains GII.4-1987, GII.4-2002, GII.4-2006, and GII.4-2009. For
each VLP, the mean percentage of control binding (percentage of the VLP bound to PGM in the presence of sera compared to the amount of VLP bound with
no sera present) was fit to a sigmoidal curve, and the mean EC50 of serum was calculated (percentage of serum required to block 50% of the VLP-PGM
interaction). Sera that did not block a particular VLP were assigned a value of 10% (2 times the upper limit of detection) for statistical analysis and placed as a data
point above the dotted line (upper limit of detection). Statistical significance was determined by one-way ANOVA with a Bonferroni posttest, and statistical
differences compared to the homotypic VLP are shown (*, P  0.05).
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probe the antigenic properties of epitope site A in preemergent
strains. When coupled with epidemiologic surveillance data, this
system could provide a mechanism for predicting future emergent
strains and for vaccine reformulation prior to epidemic seasons
(Fig. 7), providing a key public health preparedness platform and
vaccine reformulation strategy for noroviruses.
These studies, coupled with studies reported by other groups,
highlight the power of antibody-based identification of key neu-
tralizing epitopes in viral pathogens. This information provides an
opportunity to map the conformational epitopes and identify key
residues which influence immunogenicity and protective immu-
nity. When coupled with structure-guided antigen and synthetic
gene design, chimeric VLPs can be constructed with novel prop-
erties that broaden neutralization antibody responses and protec-
tive immunity even against strains not included in the original
design. This fledgling strategy promises to revolutionize the de-
sign of the next generation of vaccines, with the ultimate goal of
improving the global health of populations.
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